Oral PDE5 inhibitors remain the first-line treatment for erectile dysfunction in many clinical settings. They are familiar, easy to prescribe and effective for a proportion of patients. However, real-world practice shows that pills do not meet the needs of every man and, for some, they are not an appropriate long-term solution.
Erectile dysfunction is increasingly recognised as a condition influenced by vascular health, tissue integrity and nerve function, rather than a problem that can always be managed with on-demand medication alone.
As understanding of erectile dysfunction has evolved, so too has recognition that symptom-driven treatment alone does not address the underlying pathophysiology in many patients.
This has prompted growing interest in treatment approaches that move beyond pharmacological support.
The limitations of pill-based management
PDE5 inhibitors act by temporarily enhancing blood flow to the penis, but they do not modify the structural or vascular changes that often underpin erectile dysfunction. Conditions such as endothelial dysfunction, collagen degradation, fibrosis and venous leakage remain unaddressed.
In clinical practice, this may present as a reduced or inconsistent response, resulting in discontinuation due to patient dissatisfaction. This also does not account for treatment-related side effects.
For many patients, particularly those with mild to moderate organic erectile dysfunction, pills manage symptoms without altering disease progression.
Erectile dysfunction as a tissue and vascular condition
Erectile function depends on intact neurovascular signalling, a healthy endothelium and the structural integrity of penile tissue, particularly the tunica albuginea. Ageing, diabetes, metabolic disease and reduced tissue elasticity can compromise these systems.
When collagen structure weakens or vascular responsiveness declines, the penis becomes less able to trap and maintain blood volume, resulting in reduced rigidity or difficulty maintaining erections. These changes are structural and physiological rather than situational.
Recognising erectile dysfunction as a condition of tissue health, rather than solely a haemodynamic issue, opens the door to restorative treatment strategies.
Moving towards restorative, non-pharmacological therapies
Advances in medical technology have led to the development of energy-based therapies designed to support tissue remodelling and vascular function, rather than provide immediate functional support. These approaches aim to influence underlying erectile mechanisms through biological effects.
Radiofrequency therapy is one such modality. Low-energy radiofrequency has been used in other medical fields to stimulate collagen remodelling, improve microcirculation and support tissue health. When applied to erectile tissue, the objective is to support structural integrity, improve blood flow and contribute to neurovascular function over time.
This represents a shift from on-demand treatment towards longer-term functional support.
Vertica and the role of home-based radiofrequency therapy
Vertica is a non-invasive, clinically tested radiofrequency medical device designed for the treatment of mild to moderate erectile dysfunction. Unlike pill-based therapies, it is not used at the time of sexual activity. Treatment sessions are completed independently, with the aim of supporting natural erectile function over time.
From a clinical perspective, Vertica targets underlying vascular and tissue-related contributors to erectile dysfunction. It is drug-free and avoids systemic exposure, can be used at home to support discretion and adherence, and is intended to complement existing clinical pathways rather than replace medical assessment or follow-up.
Meaningful improvements in erectile function parameters have been observed in a clinical study, without reported adverse effects, supporting its role as a non-pharmacological option for appropriately selected patients.
Supporting clinicians in expanding treatment pathways
Thinking beyond pills does not mean abandoning pharmacotherapy. It means recognising its limitations and offering patients additional evidence-based options when appropriate.
For clinicians, this involves identifying patients who are suboptimal responders to medication, recognising contraindications or long-term dissatisfaction, considering restorative therapies earlier in the treatment pathway and supporting shared decision-making with clear, science-led explanations.
As patient expectations shift towards solutions that address root causes rather than symptoms, clinicians are increasingly asked about alternatives to medication.
A broader view of erectile dysfunction care
Erectile dysfunction is rarely driven by a single mechanism. Effective management often requires a broader view that considers vascular health, tissue integrity and patient quality of life.
Non-invasive, clinically supported technologies such as radiofrequency therapy provide an opportunity to expand treatment strategies beyond pharmacology alone.
For clinicians, thinking beyond pills means recognising erectile dysfunction as a condition with underlying vascular and tissue components, and considering clinically supported, non-invasive options such as radiofrequency therapy when medication alone is insufficient or inappropriate.
Ohh-Med Medical is developing Vertica Pro, a radiofrequency device designed for use in clinical settings. It is intended to apply the same radiofrequency principles as the home-use Vertica system within a supervised, in-clinic treatment pathway, supporting clinicians who wish to offer a non-invasive, technology-based option alongside existing erectile dysfunction care.
You can register for updates about this new platform.